Connor, Clark & Lunn Investment Management Ltd.

Position in ZNTL — Zentalis Pharmaceuticals, Inc.

CIK 1596800 VANCOUVER, A1

Position in ZNTL

as of Jun 30, 2026 · filed Aug 13, 2026 Compact

Position Value

$3,676,460

+$1,823,178 QoQ

Shares Held

758,033

-4.3% QoQ

Ownership

1.06%

of shares outstanding

% of Portfolio

0.01%

of 13F equity value

Holder Rank

#20

of 114 holders

Holding Since

Mar 2024

10 quarters on record

Voting authority Sole 100% Shared 0% None 0%

Healthcare · as of Jun 30, 2026

Connor, Clark & Lunn Investment Management Ltd. holds $648,992,404 across 104 Biotechnology names. ZNTL ranks #35 (0.6% of the industry book) .

#	Ticker	Company	Shares	Value (USD)
1	VRTX	Vertex Pharmaceuticals Inc / Ma	135,236	$67,175,777
2	IONS	Ionis Pharmaceuticals Inc	684,236	$54,253,072
3	ARWR	Arrowhead Pharmaceuticals, Inc.	625,569	$50,990,129
4	MIRM	Mirum Pharmaceuticals, Inc.	420,063	$49,176,775
5	REGN	Regeneron Pharmaceuticals, Inc.	42,465	$26,478,625
6	AXSM	Axsome Therapeutics, Inc.	97,698	$23,913,539
7	INSM	INSMED Inc	212,676	$22,675,515
8	VKTX	Viking Therapeutics, Inc.	530,607	$20,698,979

10 filing rows on record

Report Date	Value (USD)	Shares	Change	Type	Discretion	Filed
2026-06-30	$3,676,460	758,033	-4.3%	Shares	Sole	2026-08-13
2026-03-31	$1,853,282	792,001	+0.6%	Shares	Sole	2026-05-11
2025-12-31	$1,062,524	787,055	+106.7%	Shares	Sole	2026-02-10
2025-09-30	$575,041	380,822	+21.0%	Shares	Sole	2025-11-13
2025-06-30	$365,220	314,845	-12.8%	Shares	Sole	2025-08-07
2025-03-31	$574,365	361,236	+4.7%	Shares	Sole	2025-05-12
2024-12-31	$1,045,468	345,039	+50.6%	Shares	Sole	2025-02-10
2024-09-30	$843,227	229,138	+126.3%	Shares	Sole	2024-11-08
2024-06-30	$414,194	101,270	+420.1%	Shares	Sole	2024-08-09
2024-03-31	$306,862	19,471	—	Shares	Sole	2024-05-09
No filing history on record for this holder in this stock.